SCHEMBL17102728

SCHEMBL17102728

CC(C)(C)N(C(=O)O)c1cc(F)ccc1N

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.46
ALDH1A1 P00352 1/20 0.37
HDAC1 Q13547 5/20 0.35
HDAC3 O15379 3/20 0.33
NCOR2 Q9Y618 2/20 0.33
RIPK1 Q13546 5/20 0.33
HDAC2 Q92769 3/20 0.33
DPP4 P27487 1/20 0.32
DPP8 Q6V1X1 1/20 0.32
DPP9 Q86TI2 1/20 0.32
DPP7 Q9UHL4 1/20 0.32
KCNN4 O15554 1/20 0.32
KDM4E B2RXH2 1/20 0.32
POLB P06746 1/20 0.32
FADS1 O60427 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1512084 0.87 KEAP1 (0.42) KEAP1ALDH1A1HDAC1HDAC3NCOR2
SCHEMBL17102731 0.82 SMN1; SMN2 (0.39) ALDH1A1HDAC2KDM4EHTT
SCHEMBL17507931 0.81 KDM4E (0.47) ALDH1A1HDAC2KDM4E
SCHEMBL16506791 0.80 CES2 (0.40) ALDH1A1RIPK1KCNN4KDM4EHTT
SCHEMBL8802370 0.79 HSD17B1 (0.39) KEAP1HDAC1HDAC3RIPK1HDAC2
SCHEMBL17542575 0.79 CA3 (0.38) KEAP1ALDH1A1RIPK1KDM4EHTT
SCHEMBL20520835 0.78 KEAP1 (0.50) KEAP1ALDH1A1HDAC1HDAC3NCOR2
SCHEMBL247809 0.76 KDM4E (0.38) ALDH1A1HDAC1HDAC3RIPK1HDAC2
SCHEMBL26621379 0.74 HDAC1 (0.39) KEAP1ALDH1A1HDAC1HDAC3NCOR2
SCHEMBL3509717 0.74 AKR1C3 (0.33) ALDH1A1RIPK1KCNN4KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9561228-B2 ERK inhibitors and uses thereof CELGENE AVILOMICS RESEARCH, INC. (US) 2017-02-07 US disclosed
US-9504686-B2 ERK inhibitors and uses thereof CELGENE AVILOMICS RESEARCH, INC. (US) 2016-11-29 US disclosed
US-20160082008-A1 ERK INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2016-03-24 US disclosed
US-20160002176-A1 ERK INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2016-01-07 US disclosed
US-9145387-B2 ERK inhibitors and uses thereof CELGENE AVILOMICS RESEARCH, INC. (US) 2015-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002176-A1 ERK INHIBITORS AND USES THEREOF MAPK1, MAPK3, MAP4K2 KEAP1 649/4885ALDH1A1 2289/4885HDAC1 931/4885
US-20160082008-A1 ERK INHIBITORS AND USES THEREOF MAP3K20, MAP3K1, MAPK3 KEAP1 533/4885ALDH1A1 2838/4885HDAC1 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.